DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của CytRX Corporation

CytRx Corporation, a biopharmaceutical research and development company, specializes in oncology. Its drug development pipeline includes INNO-206, which is in Phase Ib clinical trial and is completing Phase Ib/II clinical trial for the treatment for soft tissue sarcomas; and tamibarotene that in Phase IIb clinical trial for the treatment of non-small-cell lung cancer and is in a clinical trial as a treatment for acute promyelocytic leukemia.

TÊN CÔNG TY / COMPANY
CytRX Corporation

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
CYTR

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare